Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11886MR)

This product GTTS-WQ11886MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11886MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12250MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ1113MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ10404MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ5679MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ2745MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ14131MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ2369MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ13169MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW